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Abstract
Background: Numerous cases of swine-origin 2009 H1N1 influenza A virus (H1N1)-associated acute respiratory
distress syndrome (ARDS) bridged by extracorporeal membrane oxygenation (ECMO) therapy have been reported;
however, complication rates are high. We present our experience with H1N1-associated ARDS and successful
bridging of lung function using superimposed high-frequency jet ventilation (SHFJV) in combination with
continuous positive airway pressure/assisted spontaneous breathing (CPAP/ASB).
Methods: We admitted five patients with H1N1 infection and ARDS to our intensive care unit. Although all
patients required pure oxygen and controlled ventilation, oxygenation was insufficient. We applied SHFJV/CPAP/
ASB to improve oxygenation.
Results: Initial PaO2/FiO2 ratio prior SHFJV was 58-79 mmHg. In all patients, successful oxygenation was achieved
by SHFJV (PaO2/FiO2 ratio 105-306 mmHg within 24 h). Spontaneous breathing was set during first hours after
admission. SHFJV could be stopped after 39, 40, 72, 100, or 240 h. Concomitant pulmonary herpes simplex virus
(HSV) infection was observed in all patients. Two patients were successfully discharged. The other three patients
relapsed and died within 7 weeks mainly due to combined HSV infection and in two cases reoccurring H1N1
infection.
Conclusions: SHFJV represents an alternative to bridge lung function successfully and improve oxygenation in the
critically ill.
Background
The swine-origin 2009 H1N1 influenza A virus has
become the predominant influenza virus worldwide
since its identification. H1N1 influenza might cause
acute respiratory distress syndrome (ARDS) and poten-
tially result in extracorporeal membrane oxygenation
(ECMO) therapy [1]. Experience from Australia and
New Zealand describes an incidence of mechanical ven-
tilation in 64.6% of H1N1 patients and 11.6% ECMO
(with a mortality of approximately 21%) treated within
the intensive care unit (ICU) [2].
Mortality rates of ARDS patients suffering from
hypoxemia and/or hypercapnia remains high [3]. In this
situation, ECMO therapy represents the standard of
bridging lung function [2]. However, ECMO therapy is
associated with unfavorable complications and high cost.
In this report, we suggest an alternative strategy to
bridge lung function: the use of superimposed high-fre-
quency jet ventilation (SHFJV) in combination with
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neous breathing (CPAP/ASB). This alternative ventila-
tion strategy is based on jet ventilation to improve
oxygenation at lower plateau pressure combined with
assisted spontaneous breathing by CPAP/ASB to
improve CO2 removal.
Methods
In winter 2009-2010, five patients with ARDS (H1N1)
were admitted to our ICU due to inadequate oxygena-
tion by conventional mechanical ventilation from out-
side hospitals. ARDS was defined according to the
definition of the American-European Consensus Confer-
ence on ARDS [4].
Microbiology
Virological and microbiological tests were performed
in bronchioalveolar lavage under sterile conditions.
Influenza A H1N1 infection was determined by real-
time reverse transcriptase-polymerase chain reaction
(RT-PCR) assay. In addition, herpes simplex virus
(HSV)-DNA, cytomegalovirus (CMV)-DNA, Epstein-
Barr virus (EBV)-DNA, RSV, and adenovirus were
tested by TAQMAN PCR. Atypical species, such as
Mycoplasma, Pneumocystis jiroveci, or Legionella were
screened through PCR. BAL, swabs, and blood cultures
were taken routinely on admission and depending on
clinical need.
Mechanical ventilation
Patients were ventilated with a Monsoon I or Monsoon
III jet ventilator (Acutronic Medical Systems, Hirzel,
Switzerland, distributed by IfM GmbH, Wettenberg,
Germany) combined with a standard respirator, Evita
XL (Draeger, Lübeck, Germany) or Hamilton G5
(Hamilton Medical, Bonaduz/Switzerland, distributed by
Heinen & Löwenstein GmbH, Bad Ems, Germany).
Weaning protocol
￿ Spontaneous breathing within 12 h after admission
￿ Positive end-expiratory pressure (PEEP) primary
12-15 mbar
￿ Ppeak (peak pressure) < 30 mbar
￿ Pmean < 20 mbar
￿ FiO2, work pressure, and frequency of jet, ASB in
adaption to blood gas analyses; goal: oxygen delivery
(DO2) normal, lactate normal, pH 7.3-7.45
￿ Supine position 135° up to 12-14 h as long as oxy-
genation benefits
￿ ECMO (QUADROX PLS and ROTAFLOW RF 32,
MAQUET GmbH &Co. KG, Rastatt, Germany)
Interventional Lung Assist (ILA Membranventilator
®,
Novalung GmbH, Talheim, Germany) when CO2 >
50 mmHg, pH < 7.3 and no progress by conservative
ventilation and sedation management
Sedation
To achieve a RASS (Richmond agitation and sedation
scale) of -3 to -4 propofol or midazolam, in two cases
additionally with g-hydroxybutanoic acid was used in
combination with remifentanil or sufentanil and
clonidine.
Antiviral medication
All patients received oseltamivir, two patients in combi-
nation with ribavirin and amantadine up to 9 days. HSV
was treated as standard with acyclovir; two patients
received foscarnet-sodium when CMV coinfection was
suspected or proven.
Results
Five patients with severe influenza A H1N1 infection
and refractory hypoxemia were ventilated between 2 and
16 days before admission. The transfer of these patients
to our ICU was due to failure to improve during con-
ventional ventilation (PEEP 10-15 mbar, pressure-con-
trolled ventilation with Ppeak up to 35 mbar, FiO2 1.0).
On admission, patients presented with a paO2/FiO2 ratio
of 58 to 79 (Murray score > 3.0; Table 1). After institution
of SHFJV, oxygenation improved in all patients within 24
h (paO2/FiO2 ratio 105-306) with a PEEP of 8 to 15 mbar,
Ppeak <3 0m b a r ,a n dP mean 15-18 mbar. Therefore, the
institution of SHFJV allowed improved oxygenation with
adequate DO2 and a simultaneous reduction of lung
injury, inducing high peak and mean pressures at the
same time. Spontaneous breathing was set during 8 h after
admission. Three patients required jet ventilation for up to
72 h. One patient required prolonged jet ventilation due
to concomitant mycoplasma pneumonia, and the other
due to persistent H1N1 pneumonia.
FiO2 was reduced from initially 1.0 to 0.4-0.6 in four
cases. However, one patient with a ventilation period of
14 days before admission due to H1N1 and concomitant
Pneumocystis jiroveci infection needed a FiO2 of 0.9 up
to day 7.
Jet ventilation was performed in three cases with a
work pressure of 1.2-1.7 bar, a frequency of 140-200/
min (Monsoon I Jet ventilator); in two patients a novel
jet ventilator was used and the work pressure was set to
0.5-0.9 bar and the frequency adjusted to 500-600/min
(Monsoon III Jet ventilator).
When only H1N1 infection was present, the oxygena-
tion deficit was the leading clinical symptom. In cases
with prolonged treatment (reinfection or concomitant
infection with HSV, Mycoplasma) hypercapnia also was
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patient ILA therapy (Figure 1). The patient with ECMO
therapy demonstrated improved oxygenation and nor-
mocapnia but deceased due to intracranial bleeding.
This patient had histologic confirmed HSV pneumonia
for 4 weeks without improvement after acyclovir/foscar-
net treatment. A similar clinical pathway was observed
in the two other patients who died.
Despite pulmonary failure, organ dysfunction was
moderate. Some patients showed liver dysfunction; two
of three nonsurvivors had acute renal failure. Vasoactive
drugs were needed initially in all patients.
From anamnesis, four patients were obese; one patient
had pre-existing medical complications (acute CMV
colitis and acute Pneumocystis jiroveci pneumonia by
ulcerative colitis). None of the patients had pre-existing
immunodeficiency, such as HIV.
Discussion
During ARDS, ECMO is seen as the standard therapy to
improve oxygenation. The CESAR study demonstrated
that in highly specialized centers, ECMO therapy may
improve long-term outcome. However, this study had
limitations within the study design, because the inter-
vention and control group were treated at different cen-
ters [5]. In a review of 62 cases with ECMO therapy, the
survival rate was 55% [6]; 17.8% of patients died as a
result of ECMO-related complications, translated into a
mortality of 8% due to ECMO alone. A retrospective U.
S. database analysis (1986-2006) demonstrated a mortal-
ity rate of 50% in patients treated with ECMO. Although
technical improvement of ECMO equipment translated
into fewer cases of circuit rupture, renal insufficiency,
pulmonary hemorrhage, inotropic medications, hypergly-
cemia, extremes of pH, arrhythmias, or hypertension
became more common [7].
The primary goal for ARDS patients is to preserve an
acceptable gas exchange without further injury to the
lungs. High-frequency jet ventilation (HFJV) and high-
frequency oscillatory ventilation (HFOV) are character-
ized by rapid delivery of small tidal volumes (Vt)( 1 - 3
ml/kg predicted body weight) at high frequencies (2.5-5
Hz). As such, Pmean during jet ventilation is comparable
to the pressure level of PEEP in conventional mechani-
cal ventilation due to its minimal Vt.Y e t ,P peak and
Pmean are markedly reduced with a reduction of tidal
hyperinflation and tidal decruitment [8]. Furthermore,
oxygen toxicity may be reduced as lower FiO2 often are
required compared with mandatory ventilation [8]. This
beneficial effect could be demonstrated in animal mod-
els of HFOV. In addition, pulmonary compliance
improved, the infiltration of polymorph nuclear leuko-
cytes was reduced, and tumor necrosis factor-a levels
attenuated. As a result, injury to alveoli and membra-
nous bronchioles was reduced [9].
HFOV mainly differs from HFJV by active in- and
expiration, whereas HFJV only uses active inspiration
and passive expiration. Thus, HFJV allows patients
spontaneous breathing, preserving muscles of diaphragm
and intercostal musculature. This is a major advantage,
because early spontaneous breathing significantly
reduces deleterious organ-organ interactions, e.g., lung-
liver interactions, and improves liver perfusion [10].
One major problem of jet ventilation is CO2 clearance
d u et ov e r yl o wV t. There are two options in resolving
this problem. The simplest approach is to establish
spontaneous breathing. However, patients might be
sedated and therefore need superimposed CPAP/ASB to
improve tidal inflation until sedation is adapted. In the
case of severe hypercapnia, the use of Interventional
Lung Assist (ILA) can improve CO2 clearance.
Table 1 Demographic data of patients, ICU admission
data, and arterial blood gases with start of jet
ventilation
Patient no. 1 2 3 4 5
Age [yr] 38 42 18 25 57
Gender fm m m m
Chronic disease/
condition
Obesity Obesity – Ulcerative
colitis
Obesity
Scores at admission
SOFA 91 5 1 0 1 4 2 9
SAPS II 29 66 22 30 10
APACHE II 27 26 26 23 26
Murray score 3.75 3.75 3.25 3.25 3.5
Laboratory findings at admission
LDH [U/l] 2245 708 1644 525 1348
CK [U/l] 2440 24 4335 58 534
CRP [mg/dl] 40.67 37.9 2.12 16.06 29.9
PCT [ng/ml] 2.5 0.9 4.1 1.2 0.7
Leukocytes [/nl] 4.19 12.55 7.79 42.4 2.77
Arterial blood gases at admission
pH 7.358 7.270 7.352 7.40 7.33
paO2 [mmHg] 79.3 79.1 68.7 58 75.6
paCO2 [mmHg] 48.2 66.0 45.8 55 54.6
FiO2 1.0 1.0 1.0 1.0 1.0
Lactate [mg/dl] 19 29 10 97 10
Arterial blood gases within 24 h after start of SHFJV
pH 7.356 7,539 7.291 7.30 7.343
paO2 [mmHg] 113 122 188 105 133
paCO2 [mmHg] 55.7 38,0 49.7 70.1 47,5
FiO2 0.8 0.4 1.0 1.0 0.8
Lactate [mg/dl] 14 31 9.0 80 12
SOFA = sequential organ failure score; SAPS II = Simplified Acute Physiology
Score II; APACHE II = Acute Physiology and Chronic Health Evaluation II; LDH
= lactate dehydrogenase; CK = creatinine kinase; CRP = C-reactive protein;
paO2 = arterial oxygen fraction; paCO2 = arterial carbon dioxide fraction; FiO2
= oxygen fraction.
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-explained, in part, by patient selection. All of our
patients presented in this report were admitted with
fixed hypoxemia despite optimized conventional ventila-
tion. Two patients presented a prolonged period of
hypoxemia and mechanical ventilation before admission.
One of these patients was already on mechanical venti-
lation 14 days due to septic CMV-colitis and Pneumo-
cystis jiroveci pneumonia with poor prognosis. The
other patient was admitted to our ICU after a prolonged
period of severe hypoxemia and septic shock with hypo-
perfusion. All five patients had a HSV-PCR-positive
BAL, confirmed via lung biopsy in one patient. Viral
coinfection with HSV may cause and prolongs a status
of persistent immunosuppression during severe H1N1
infection, which is associated with a high risk of death.
This hypothesis is supported by findings of Monsalvo
and colleagues, who found pathogenic immune
Figure 1 Detailed patient data of ventilator treatment and viral infection.
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for the unusual age distribution of severe H1N1 infec-
tions [11].
Conclusions
Although jet ventilation is actually not in the focus of
ARDS treatment, we were able to demonstrate that
SHFJV represents an alternative of lung-protective venti-
lation during ARDS. Compared with ECMO, it is easier
to use, associated with fewer complications, cost-effec-
tive, and can be used in secondary and tertiary centers.
Therefore, SHFJV is an alternative approach to improve
lung function and oxygenation in patients suffering
from ARDS. Nevertheless, this report is limited by the
small study size, including a heterogeneous patient col-
lective. Therefore, a controlled study with SHFJV to
treat patients with ARDS is required for an evidence-
based conclusion.
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